A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients
Journal
Scientific Reports
Journal Volume
10
Journal Issue
1
Date Issued
2020
Author(s)
Abstract
This study aimed to validate the long-term prognostic value of a new clinical-genomic model, Distant Genetic Model-Clinical Variable Model 6 (DGM-CM6), developed in Asia as a prognostic panel for all subtypes of breast cancer. We included 752 operable stage I–III breast cancer patients representing all subtypes treated from 2005 to 2014 as the validation cohort. The median follow-up was 95.8?months. The low- and high-risk patients classified by DGM-CM6 (RI-DR) had significant differences in 10-year distant recurrence-free interval (DRFI) (94.1% vs. 85.0%, P < 0.0001) and relapse-free survival (RFS) (90.0% vs. 80.5%, P = 0.0003). External validation using EMTAB-365 dataset showed similar observation (P < 0.0001). DGM-CM6 was an independent prognostic factor by multivariate analysis with hazard ratios of 3.1 (1.6–6.0) for RFS (P = 0.0009) and 3.8 (1.6–9.0) for DRFI (P = 0.0028). Comparing the C-index of DGM-CM6 and PAM50-ROR scores, the former performed better than the latter in predicting long-term DRFI and RFS, especially in N0, ER/PR-positive, and HER2-negative patients. ? 2020, The Author(s).
SDGs
Other Subjects
adult; aged; biological model; breast tumor; cancer staging; female; gene regulatory network; genetics; human; middle aged; multivariate analysis; pathology; prognosis; survival analysis; very elderly; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Gene Regulatory Networks; Humans; Middle Aged; Models, Genetic; Multivariate Analysis; Neoplasm Staging; Prognosis; Survival Analysis
Publisher
Nature Research
Type
journal article